Udifitimod
Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1883345-06-9
- Formule: C25H33NO2
- Masse moléculaire:379.54
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
S1PR1 |
Udifitimod (0.1, 0.5 mg/kg; p.o.; once daily for 50 days) reduces the clinical score as well as the paw histology score in the collagen-induced arthritis (CIA) model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 weeks, C57BL/6 female mice (autoimmune encephalomyelitis model (EAE))[2]
-
Dosage:0.1, 0.5 mg/kg
-
Administration:P.o.; once daily for 21 days
-
Result:Showed a dose-dependent reduction in clinical scores for inflammation.
-
Animal Model:DBA/1 mice (collagen-induced arthritis (CIA) model)[2]
-
Dosage:0.1, 0.5 mg/kg
-
Administration:P.o.; once daily for 50 days
-
Result:Dose dependently reduced both the clinical score as well as the paw histology score following the dosing regimens.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1883345-06-9
-
Masse moléculaire 379.54
-
Formule C25H33NO2
-
SMILES
OC[C@]1(N)C[C@@H](C2=CC=C3C[C@H](CCC4=CC=CC=C4OC)CCC3=C2)CC1
-
Synonyms
BMS-986166
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Bihorel S, et al. Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan;10(1):8-21. [Content Brief]
[2]. Gilmore JL, et al. Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials. J Med Chem. 2019 Mar 14;62(5):2265-2285. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Udifitimod Related Classifications
HY-119245 Related Classifications
Powered by Bioz